The Cooper Companies heads into the final week of April with the stock down 8.3% on the week to $61.34, yet options traders have sharply flipped toward calls — a striking contrast to the broader healthcare selloff dragging peers lower.
The most unusual signal right now is in the options market. The put/call ratio collapsed to 0.64 on Tuesday — nearly three standard deviations below its 20-day average of 1.00. That is one of the most call-skewed readings COO has logged in the past year; the 52-week range runs from 0.20 to 1.72, and Tuesday's print is comfortably in the bullish half of that band. This is not a market hedging against further downside. Despite a month that has erased 12% of value, options flow has swung decisively toward upside exposure — an unusual divergence worth watching. For context, through most of March and early April, the PCR was running consistently above 1.0, reflecting genuine defensive positioning. That has now reversed sharply.
Short interest, by contrast, has been quietly unwinding. Shorts declined roughly 8% over the week to 2.7% of free float. Over the past 30 days, estimated short interest has fallen nearly 20% in share count. With a cost to borrow running at just 0.54% and availability still loose, there is nothing in the lending market suggesting forced activity. The ORTEX short score of 35 ranks in the 51st percentile — precisely mid-table, and trending slightly lower across the past two weeks. This is not a crowded short. Peers and both suffered steeper weekly losses (-16.7% and -9.6% respectively), suggesting COO is absorbing broad sector pressure without shorts piling in.
The Street remains cautiously constructive but with meaningful dispersion. Five analysts carry a Hold consensus as of mid-April. The most recent actions, following the March 6 Q1 print, were largely maintenance moves: Barclays lifted its target to $103 (Overweight), Needham raised to $101 (Buy), while Citigroup trimmed modestly to $87 (Neutral). Goldman Sachs carries an outlier Sell, with a target of $71 — the only firm explicitly bearish. With the stock now trading at $61.34, it has blown through every price target on the bearish end of the range; the Goldman target now sits 16% above the current price. On valuation, the trailing P/E has compressed to roughly 13.3x and EV/EBITDA to 10.8x — multiples down meaningfully over the past month. The earnings yield of ~7.5% reflects a stock that has re-rated sharply lower.
The bull case centres on Cooper's dual-segment structure — contact lenses and women's health — and the potential catalyst of a formal business review that could unlock value through separation. Bears point to e-commerce pricing headwinds in the contact lens division and competitive pressure on Paragard, the copper IUD that anchors the CooperSurgical revenue mix. Franklin Resources added over 2 million shares in Q1 2026, a notable addition at the top-10 holder level. Diamond Hill similarly added 2.7 million shares, making it a new meaningful position. Both moves suggest at least some active managers stepped in during the earlier drawdown — though those purchases were made at prices well above current levels.
The next earnings event is scheduled for June 4. Historically, COO's post-earnings reactions have been consistently negative: the last two releases each produced a one-day move of roughly -5% to -7% and a five-day follow-through of around -13%. With the stock already down 12% over the past month, the June print becomes the next focal point for whether the valuation compression has run its course or if the fundamental story has genuinely deteriorated.
See the live data behind this article on ORTEX.
Open COO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
